Table 1.

CAR cell clinical products currently tested in AML, HL and MM patients (as of September 30, 2017)

	Product	Target	Tumor	Start date	Academia	Industry	Vector	Construct (scFv-Hinge-TM-CD-SD)	Additional features	Active clinical trials	Reports
1	CART-LeY	LeY	Myeloid malignancies	Oct-16	Southwest Hospital, China	NA	NA	NA	NA	NCT02958384	NA
2	CM-CS1 T	NKG2DL	AML, MDS, MM	Mar-15	DFCI, USA	Ceylad	Retro	NKG2D-CD3ζ	Single infusion of autologous CM-CS1 cells	NCT02203825*	Nikiforow S, 2016[158]
3	CART33	CD33	AML	Apr-13	Chinese PLA Hospital, China	NA	Retro	AM402974.1-41BB-CD3ζ	Autologous	NCT01864902	Wang Q-S, 2015[39]
4	CART33	CD33	AML	Oct-15	Chinese PLA Hospital, China	NA	NA	NA	Allogeneic	NCT02799680	NA
5	CD33.CAR T	CD33	Myeloid malignancies	Oct-16	Southwest Hospital, China	NA	NA	NA	NA	NCT02958397	NA
6	Allo-CARpNK-33	CD33	AML	Oct-16	FPHH, China	PersonGen BioTherapeutics	Viral	NA-CD28-41BB-CD3ζ	NK-92 clinical grade cell line	NCT02944162	NA
7	CD33.CAR T	CD33	AML	Aug-17	MDACC, USA	NA	Lenti		Autologous, EGFR-derived kill switch	NCT03126864	Song D, 2016 [99]
8	CART-133	CD133	Solid tumors1, AML, ALL	Sep-15	Chinese PLA Hospital, China	NA	Lenti	HW350341.1-CD137-CD3ζ	NA	NCT02541370	Feng KC, 2017[159]
9	RNA CART123	CD123	AML	Dec-15	UPenn, USA	Novartis	mRNA	NVS2-41BB-CD3ζ	mRNA	NCT02623582*	NA
10	CART123	CD123	AML	Dec-15	NCI, USA	NA	Lenti	NA-CD28-CD3ζ-EGFRt	Autologous or donor-derived, EGFRt	NCT02159495	NA
11	CD123.CAR T	CD123	Myeloid malignancies	Oct-16	Southwest Hospital, China	NA	NA	NA	NA	NCT02937103	NA
12	CAR123 T	CD123	AML	Mar-17	AHAMMS, China	Shenzhen Geno-Immune Medical Institute	NA	CD123CAR-41BB-CD3zeta-EGFRt	Allogeneic	NCT03114670	NA
13	UCART123	CD123	AML	Jun-17	NA	Cellectis	Lenti	NA-41BB-CD3ζ	TALEN-mediated CD52-TRAC ablation	NCT03190278**	NA
14	Anti-CD7 CAR-pNK	CD7	AML T cell malignancies	Mar-16	NA	PersonGen BioTherapeutics (Suzhou) Co., Ltd.		NA-CD28-41BB-CD3ζ	Allogeneic, clinical-grade NK-92 cell line	NCT02742727	NA
15	4SCAR123	CD123	AML	Jul-17	FAHZU, China	NA	Lenti	NA/CD28/CD137/CD27/CD3ζ-iCasp9	4th generation iCaspase9	NCT03125577	Luo Y, 2015[49]
16	CART123 CART33	CD123 CD33	AML,MDS ALL	Sep-17	Zhujiang Hospital, China	NA	NA	NA	Combined with Eps8 peptide specific DC	NCT03291444	NA
17	CAR.CD30	CD30	HL, NHL	May-11	BCM, USA	NA	Retro	NA-CD28-CD3ζ	Autologous CAR.CD30 EBV specific-CTLs	NCT01192464*	NA
18	CAR.CD30	CD30	HL	Oct-11	BCM, USA	NA	Retro	NA-CD28-CD3ζ	NA	NCT01316146*	Ramos, 2015[70]
19	4SCAR30273	CD30	HL	Mar-14	Peking University, China	NA	Lenti	NA-CD28-CD137-CD27-CD3ζ	4th generation iCaspase9	NCT02274584	Ying Z-T, 2015[160]
20	CART30	CD30	HL	Oct-14	Chinese PLA, Hospital, China	CBMG	Lenti	AJ878606.1-CD137ζ -GFP	Repeated infusions	NCT02259556	Wang C-M, 2017[71]
21	ATLCAR.CD30	CD30	HL, NHL	Jun-16	BCM, USA	NA	Retro	HRS3-CD28-CD3ζ	3rd line therapy	NCT02690545,	NA
22	ATLCAR.CD30	CD30	HL, NHL	May-16	BCM, USA	NA	Retro	HRS3-CD28-CD3ζ	2nd line therapy	NCT02663297	NA
23	CD30.CAR T	CD30	HL, NHL	Oct-16	Southwest Hospital, China	NA	NA	NA	NA	NCT02958410	NA
24	Anti-CD30 CAR T	CD30	Hl, NHL	Mar-17	NCI, USA	NA	Retro	NA	Autologous T cells, fully human anti-CD30 CAR	NCT03049449	Kochenderfer J, 2017 [161]
25	CD30.CAR T	CD30	HL, NHL	May-17	BCM, USA	NA	Retro	NA-CD28-CD3ζ	No previous autologous tHSCT	NCT02917083	NA
26	CART	CD123, CD30, BCMA	Myeloid/lymphoid malignancies	Dec-16	NA	Hebei Senlang Biotechnology	NA	NA	Autologous	NCT03121625	NA
27	Anti-BCMA CAR-T	BCMA	MM	Aug-14	NCI, USA	NA	Retro	Anti-BCMA-CD28-CD3z	Autologous	NCT02215967	Ali SA, 2016[80]
28	CART-BCMA	BCMA	MM	Sep-15	UPenn, USA	Novartis	NA	Anti-BCMA-41BB-CD3z	Autologous	NCT02546167	NA
29	LCAR-B38M	BCMA	MM	Oct-15	NA	Nanjing Legend Biotech	NA	NA	NA	NCT03090659	Frank XF, 2017 [162]
30	bb2121	BCMA	MM	Jan-16	NA	Bluebird Bio	Lenti	Anti-BCMA-41BB-CD3z	Autologous	NCT02658929	Berdeja J, 2017[163]
31	CART-138/BCMA	CD138/BCMA	MM	Sep-16	FAHSU, China	NA	NA	NA	Autologous or allogeneic	NCT03196414	NA
32	Anti-BCMA CAR-T	BCMA	MM, Leukemia, Lymphoma	Oct-16	Southwest Hospital, China	NA	NA	NA	NA	NCT02954445	NA
33	Anti-BCMA CAR-T	BCMA	MM	Feb-17	SAHHUTCM, China	NA	Retro	Anti-BCMA-41BB-CD3z	Autologous	NCT03093168	NA
34	Anti-BCMA CAR-T	BMCA	MM, PCL	Feb-17	MSKCC, USA	Juno Therapeutics	NA	EGFRt/Anti-BCMA-41BB-CD3z	NA	NCT03070327	NA
35	bb21217	BCMA	MM	Aug-17	NA	Bluebird Bio	Lenti	Anti-BCMA-41BB-CD3z	CART cells cultured with a PI3k inhibitor	NCT03274219	NA
36	P-BCMA-101	BCMA	MM	Sep-17	NA	Poseida Therapeutics	piggyBAC transposon	Anti-BCMA.FN3-CD8a-41BB-CD3z	Selection and safety switch genes	NCT03288493	Hermanson DL, 2016[164] Barnett BE, 2016[165]
37	CART-138	CD138	MM	Jun-13	Chinese PLA Hospital, China	NA	Retro	Anti-CD138-41BB-CD3z	Autologous or allogeneic	NCT01886976	Guo B, 2016[166]
38	CART-19	CD19	MM	May-14	UPenn, USA	Novartis	Lenti	FMD63scFv-41BB-CD3z	Autologous, r/r MM	NCT02135406	Garfall A, 2015[167] Garfall A, 2016[168]
39	CART-19	CD19	MM	Jun-16	UPenn, USA	Novartis	Lenti	FMD63scFv-41BB-CD3z	Autologous, day+60 post first-line autoHSCT	NCT02794246	NA
40	CAR-K+ T	κ light chain	MM, CLL, NHL	Jul-09	BCM	NA	Retro	NA-CD28-CD3z	Autologous	NCT00881920	Ramos, 2016[169]

^*not recruiting;

^**suspended participant recruitment

¹Liver, pancreatic, brain, breast, ovarian, colorectal

DFCI, Dana-Farber Cancer Institute; FPHH, The First People’s Hospital of Hefei; MDACC MD Anderson Cancer Center; UPenn University of Pennsylvania; NCI National Cancer Institute; AHAMMS Affiliated Hospital to Academy of Military Medical Sciences; FAHZU, The First Affiliated Hospital of Zhejiang University; BCM Baylor College of Medicine; FAHSU, The First Affiliated Hospital of Soochow University; SAHHUTCM The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, MSKCC Memorial Sloan Kettering Cancer Center, TM trans-membrane domain, CD costimulatory domain, SD signaling domain, autoHSCT autologous hematopoietic transplantation. NA not available, PCL plasma cell leukemia. Retro: retroviral vector; Lenti: lentiviral vector. r/r: relapsing or refractory; TRAC: TCR-α constant region; DC: dendritic cells; FN3: human tenascin fibronectin type III consensus sequence